SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): July 21, 2005
ISIS PHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in Charter)
Delaware
(State or Other Jurisdiction of Incorporation)
000-19125 | | 33-0336973 |
(Commission File No.) | | (IRS Employer Identification No.) |
1896 Rutherford Road
Carlsbad, CA 92008
(Address of Principal Executive Offices and Zip Code)
Registrant’s telephone number, including area code: (760) 931-9200
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 1.01 Entry into a Material Agreement.
On July 20, 2005, Isis Pharmaceuticals, Inc., through its Ibis division (the “Company”), was granted a contract for approximately $2.6 million from the Defense Advanced Research Projects Agency (DARPA) under a subcontract from San Diego-based Science Applications International Corporation (SAIC). On July 21, 2005, the Company issued a press release announcing its Ibis division has been granted contracts for approximately $5 million, which amount includes the DARPA contract, from several government agencies to continue advancing development of applications to support the initial operations of the TIGER (Triangulation Identification for Genetic Evaluation of Risks) biosensor system.
Item 9.01. Financial Statements and Exhibits.
(c) Exhibits.
99.1 | | Press Release dated July 21, 2005. |
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| ISIS PHARMACEUTICALS, INC. |
| | | |
| | | |
Dated: July 21, 2005 | By: | | /s/ B. Lynne Parshall |
| | B. LYNNE PARSHALL |
| | Executive Vice President, |
| | Chief Financial Officer and Director |
| | | | |
3
INDEX TO EXHIBITS
99.1 | | Press Release dated July 21, 2005. |
4
